Urinary incontinence: Newer pharmacotherapeutic trends

Current Opinion in Obstetrics and Gynecology

Volumn 15, Issue 5, 2003, Pages 419-427

  Huggins, Melissa E ^a,d   Bhatia, Narender N ^b   Ostergard, Donald R ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Long Beach Memorial Women's Hospital   (United States)

^d Ostergard Female Urology and Gynecology Partnership Medical Group   (United States)

Author keywords

Overactive bladder; Pharmacologic therapy; Stress incontinence

Indexed keywords

ALFUZOSIN; CAPSAICIN; CLENBUTEROL; CROMAKALIM; DARIFENACIN; DESMOPRESSIN; DILTIAZEM; DOXAZOSIN; DULOXETINE; ESTROGEN DERIVATIVE; FLAVOXATE; HYOSCYAMINE; IMIPRAMINE; ISOPRENALINE; MIDODRINE; NIFEDIPINE; OXYBUTYNIN; PINACIDIL; PRAZOSIN; PROPANTHELINE BROMIDE; PROPIVERINE; SALBUTAMOL; SOLIFENACIN; TAMSULOSIN; TENIDAP; TERBUTALINE; TERODILINE; TOLTERODINE; TROSPIUM CHLORIDE; UNINDEXED DRUG;

CENTRAL NERVOUS SYSTEM DISEASE; COMORBIDITY; CONSTIPATION; DEVICE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; ECONOMIC ASPECT; ERYTHEMA; FEMALE; HUMAN; HYPONATREMIA; NAUSEA; ORTHOSTATIC HYPOTENSION; OVERACTIVE BLADDER; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SEDATION; SIDE EFFECT; STRESS INCONTINENCE; SYMPTOMATOLOGY; TREATMENT OUTCOME; URINE INCONTINENCE; VERTIGO; VISUAL DISORDER; WATER RETENTION; XEROSTOMIA;

FEMALE; HUMANS; URINARY INCONTINENCE, STRESS; URINARY TRACT;

EID: 0142216264     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-200310000-00011     Document Type: Review

References (57)

1. Thom D. Variation in estimates of urinary incontinence prevalence in the community: effects of differences in definition, population characteristics, and study type. J Am Geriatr Soc 1998; 46:473-480.
2. Burgio K, Ives D, Locher J, et al. Treatment seeking for urinary incontinence in older adults. J Am Geriatr Soc 1994; 42:208-212.
3. Hiral K, Sumi T, Kanaoka Y, et al. Female urinary incontinence: diagnosis, treatment and patients' concerns. Drugs Today 2002; 38:487-493.
4. Bogner H, Gallo J, Sammel M, et al. Urinary incontinence and psychological distress in community-dwelling older adults. J Am Geriatr Soc 2002; 50:489-495. Addresses the degree of psychological stress associated with functional impairment from urinary incontinence.
5. Melville J, Walker E, Katon W, et al. Prevalence of comorbid psychiatric illness and its impact on symptom perception, quality of life, and functional status of women with urinary incontinence. Am J Obstet Gynecol 2002; 187:80-87. Investigates types of incontinence and incidence of psychiatric disease.
6. Kessler R, Berglund P, Demler O. The epidemiology of major depressive disorder results from the national comorbidity survey replication. JAMA 2003; 289:3095-3105.
7. Bogner H, Gallo J, Swartz K, et al. Anxiety disorders and disability secondary to urinary incontinence among adults over age 50. Int J Psychiatry Med 2002; 32:141-154. Shows increase in anxiety disorders among an incontinent population.
8. Nygaard I, Turvey C, Burns T, et al. Urinary incontinence and depression in middle-aged United States women. Obstet Gynecol 2003; 101:149-156. Correlates the severity of incontinence and incidence of depression.
9. Wilson L, Brown J, Shin G, et al. Annual direct cost of urinary incontinence. Obstetr Gynecol 2001; 98:398-406.
10. de Groat W. A neurologic basis for overactive bladder. Urology 1997; 50 (Suppl 6A):36-52.
11. Andersson K. Advances in the pharmacologic control of the bladder. Exp Phys 1999; 84:195-213.
12. Jensen Jr D. Pharmacological studies of uninhibited neurogenic bladder II. The influence of cholinergic excitatory and inhibitory drugs on the cystometrogram of neurological patients with normal and uninhibited neurogenic bladder. Acta Neurol Scand 1981; 64:175-195.
13. Caulfield M, Birdsall N. International Union of Pharmacology XVII: classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998; 50:279-290.
14. Kelleher C, Cardozo L, Khullar V, Salvatore S. A medium-term analysis of the subjective efficacy and treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 1997; 104:988-993.
15. Anderson R, Mobley D, Blank B, et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. J Urol 1999; 161:1809-1812. Multi-center randomized, double-blinded trial comparing efficacy and side effect profile of immediate release oxybutynin with controlled release oxybutynin.
16. Sathyan D, Chancellor M, Gupta S. Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride. Br J Clin Pharmacol 2001; 51:409-417.
17. Gupta S, Sathyan G. Pharmokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol 1999; 39:289-296.
18. Chapple C. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 2000; 55 (Suppl 5A):33-45.
19. Madersbacher H, Halaska M, Voight R, et al. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU lnt 1999; 84:646-651.
20. Yoshimura N, Chancellor, B. Current and future pharmacological treatment for overactive bladder. J Urol 2002; 168:1897-1013. Excellent review of the pharmacologic options and mechanisms of overactive bladder.
21. Nilvebrant L. The mechanism of action of tolterodine. Rev Contemp Pharmacother 2000; 11:13-27.
22. Van Kerrebroeck P, Kreder K, Jonas U, et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001; 57:414-421.
23. Sussman D, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET). Curr Med Res Opin 2002; 18:177-184. Prospective trial comparing patients' perception of improvement of their overactive bladder symptoms with tolterodine-ER and oxybutynin-ER.
24. Gulliford G, Bidmead J. Management of Incontinence. Pharm J 2001; 267:230-232.
25. Fusgen I, Hauri D. Trospium chloride: an effective option for medical treatment of bladder overactivity. Int J Clin Pharmacol Ther 2000; 38:223-234.
26. Booth C, Pascoe D. A comparison of newer drug treatments for urinary incontinence. Hosp Pharm 2002; 9:69-75. Discussion of dosing, side-effect profile and clinical trials of oxybutynin, propiverine hydrochloride, tolterodine, and trospium chloride.
27. Napier C, Gupta P. Darifenacin is selective for the human recombinant M3 receptor subtype. Trial 445. Pfizer, Inc., NY, USA; 2002. pp. 1-2.
28. Mundy A, Abrams P, Chapple C, et al. Darifenacin, the first selective M3 antagonist for overactive bladder: comparison with oxybutynin on ambulatory urodynamic monitoring and salivary flow. International Continence Society, Tokyo, Japan; 2001.
29. Appell R, Chancellor M, Zobrist H, et al. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc 2003; 78:696-702. Randomized, two-way crossover study comparing oxybutynin-TDS with oxybutynin-ER by measuring levels of active metabolite and corresponding adverse effects.
30. Dmochowski R, Davilla G, Zinner N, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002; 168:580-586. Phase III, placebo-controlled study comparing efficacy of three doses of the oxybutynin-TDS with placebo. Side effects compared with placebo were also reported.
31. Davila G, Daugherty C, Sanders S, et al. A short-term, multicenter, randomized double-blind dose titration study of efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001; 166:150-151.
32. Davila G, Singh A, Karapanagiotou I. Are women with urogenital atrophy symptomatic? Am J Obstet Gynecol 2003; 188:382-388. Prospective, randomized trial correlating histologic measurements of vaginal atrophy with symptoms of atrophy.
33. Schroder A, Levin R, Kogan B, et al. Absorption of oxybutynin from vaginal inserts: drug blood levels and the response of the rabbit bladder. Urology 2000; 56:1063-1067.
34. Collas D, Malone-Lee J. The pharmacokinetic properties of rectal oxybutynin: a possible alternative to intravesical administration. Neurourol Urodyn 1997; 16:346-489.
35. Fowler C. Intravesical treatment of overactive bladder. Urology 2000; 55 (Suppl 5A):60-64.
36. Andersson K, Appell R, Awad S, et al. Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, editors. Incontinence, 2nd International Consultation on Incontinence. UK: Plymbridge Distributors Ltd, Plymouth, UK; 2002. pp. 479-511. Normal and pathologic urologic neurology is reviewed to explain the pharmacokinetics of past, current and future pharmacologic treatment of incontinence.
37. Wein A, Rovner E. Pharmacologic management of urinary incontinence in women. Urol Clin North Am 2002; 29:537-550, viii. Product review of past, current and prospective pharmacologic therapy for urinary incontinence.
38. Andersson K, Andersson P, Fovaeus M, et al. Effects of pinacidil on bladder muscle. Drugs 1988; 36 (Suppl 7):41-49.
39. Guarneri L, Robinson E, Testa R. A review of flavoxate: pharmacology and mechanism of action. Drugs Today 1994; 30:91-98.
40. Chapple C, Parkhouse H, Gardener C, et al. Double-blind, placebo-controlled, cross-over study of flavoxate in the treatment of idiopathic detrusor instability. Urology 1990; 66 (Suppl 5A):491-494.
41. Chancellor M. Discussion: resiniferatoxin - preliminary data. Urology 2000; 55 (Suppl 5A):65.
42. Smith C, Franks M, McNeil B, et al. Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol 2003; 169:1896-1900. Evaluation on the effect of botulinum toxin A injection site and frequency of bladder contraction on the sympathetic and parasympathetic nervous systems.
43. Schulte-Baukloh H, Michael T, Schobert J, et al. Efficacy of botulinum-A toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. Urology 2002; 59:325-327.
44. Klutke J, Bergman A. Nonsurgical treatment of stress urinary incontinence. In: Bent A, Ostergard D, Cundiff G, Swift S, editors. Ostergard's urogynecology and pelvic floor dysfunction. 5th edn. Lippincott Williams & Wilkins; 2003. pp. 450-452.
45. Collste C, Lindskog M. Phenylpropanolamine in the treatment of stress urinary incontinence; double-blind, placebo-controlled study in 24 patients. Urology 1987; 30:398.
46. Thor K, Katofiasc M. Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of the lower urinary tract function in the chloralose-anesthetized female cat. J Pharmacol Exp Ther 1995; 274:1014-1024.
47. Kernan W, Viscoli C, Brass L, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000; 343:1826-1832.
48. Norton P, Zinner N, Yalcin I, et al. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol 2002; 187:40-47. Double-blind, randomized study, placebo-controlled study evaluating the safety and efficacy of duloxetine.
49. Zinner N, Dmochowski, Miklos J, et al. Duloxetine versus placebo in the treatment of stress urinary incontinence (SUI): phase III trial. Eli Lilly and Company; 2002.
50. Griebling T, Nygaard I. The role of estrogen replacement therapy in the management of urinary incontinence and urinary tract infection in postmenopausal women. Endocrinol Metab Clin North Am 1997; 26:347-360.
51. Zoubina EV. Expression of estrogen receptors alpha and beta by sympathetic ganglion neurons projecting to the proximal urethra of female rats. J Urol 2003; 169:382-385. Animal study identifying urogenital target tissues of estrogen replacement.
52. Hendrix S, McNeeley S. Urinary incontinence and menopause: update on evidence-based treatment. Medical Education Collaborative; 28 October 2002.
53. Leclair D, Anandarajah G. Effects of estrogen deprivation: vasomotor symptoms, urogenital atrophy, and psychobiologic effects. Clin Fam Pract 2002; 4:27-39. A literature review discussing the physiology and treatment of hypoestrogenic symptoms.
54. Tsai E, Yang C, Chen H, et al. Bladder neck circulation by Doppler ultrasonography in postmenopausal women with urinary stress incontinence. Obstetr Gynecol 2001; 98:52-56.
55. Foster D, Palmer M, Marks J. Effect of vulvovaginal estrogen on sensorimotor response of the lower genital tract: a randomized controlled trial. Obstet Gynecol 1999; 94:232-237.
56. Grady D, Brown J, Vittinghoff E, et al. Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Replacement Study. Obstet Gynecol 2001; 97:116-120.
57. Jackson S, Shepherd A, Brooks S, Abrams P. The effect of oestrogen supplementation on post-menopausal urinary stress incontinence. Br J Obstet Gynecol 1999; 106:711-718.